| グレード0 | 激しい運動をしたときだけ息切れがある。 |
| グレード1 | 平坦な道を早足で歩く、あるいは緩やかな上り坂を歩くときに息切れが ある。 |
| グレード2 | 息切れがあるので、同年代の人より平坦な道を歩くのが遅い、あるいは 平坦な道を自分のペースで歩いているとき、息切れのために立ち止まる ことがある。 |
| グレード3 | 平坦な道を約 100m、あるいは数分歩くと息切れのために立ち止まる。 |
| グレード4 | 息切れがひどく家から出られない、あるいは衣服の着替えをするときに も息切れがある。 |
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/10/29 21:44:21」(JST)
| This article does not cite any sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (April 2012) (Learn how and when to remove this template message) |
The mission of the Multiple Myeloma Research Consortium (MMRC) is to champion collaboration with and integration across academia and industry and to focus on speed and innovation to bring the most promising multiple myeloma treatments to patients faster. It was founded by Kathy Giusti, a myeloma patient and Founder and Chief Executive Officer of the Multiple Myeloma Research Foundation (MMRF).
The MMRC comprises 14 Member Institutions nationwide that form its clinical trials network. It is led by an Executive Committee in Norwalk, Connecticut, and a Steering Committee and Progress Review Committee composed of researchers from MMRC Member Institutions. The MMRC also includes a shared Tissue Bank of annotated tissue and peripheral blood samples from multiple myeloma patients.
The MMRC currently comprises fourteen world-renowned academic institutions: Dana-Farber Cancer Institute, H. Lee Moffitt Cancer Center & Research Institute, Mayo Clinic, City of Hope National Medical Center, Emory University, Indiana University, Hackensack University Medical Center, Ohio State University Comprehensive Cancer Center, Saint Vincent Catholic Medical Center, University Health Network (Princess Margaret Cancer Centre), University of California, San Francisco Medical Center, University of Chicago, University of Michigan, and the Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.
The MMRC Tissue Bank serves as a “bridge” between laboratory and clinical research conducted by the MMRC and is a resource to advance the MMRC Multiple Myeloma Genomics Initiative.
The MMRC is focused on advancing Phase I and Phase II clinical trials of novel compounds and combination approaches. To date, the MMRC has opened through its clinical trials network 22 clinical trials with industry partners – including Novartis, Celgene, Merck, and Proteolix. MMRC clinical trials are also designed to include correlative studies to better understand what drugs are most effective in treating various sub-groups of patients with myeloma, laying the foundation for the development of personalized medicine.
The MMRC Multiple Myeloma Genomics Initiative comprehensive genomic analysis program. It was designed to rapidly accelerate progress made against multiple myeloma by significantly improving the understanding of the biology of the disease. It is spearheaded by the MMRC and in collaboration with the Broad Institute and the Translational Genomics Research Institute (TGen).
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
| リンク元 | 「慢性閉塞性肺疾患」 |
| 関連記事 | 「mM」 |